Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ponatinib + Prednisone + Vincristine Sulfate |
Synonyms | |
Therapy Description |
Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748, PMID: 19878872). Iclusig (ponatinib) is FDA approved for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL) as well as ABL1 T315I CML and ABL1 T315I Ph positive ALL (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ponatinib | Iclusig | AP24534 | ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 32 DDR1 Inhibitor 10 DDR2 inhibitor 7 FGFR Inhibitor (Pan) 26 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-alpha Inhibitor 9 RET Inhibitor 53 SRC Inhibitor 31 VEGFR Inhibitor (Pan) 36 | Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748, PMID: 19878872). Iclusig (ponatinib) is FDA-approved for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) as well as ABL1 T315I CML and ABL1 T315I Ph-positive ALL, and in combination with chemotherapy for newly diagnosed Ph-positive ALL (FDA.gov). |
Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). | |
Vincristine Sulfate | Oncovin | 22-Oxovincaleukoblastine|vincristine | Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03589326 | Phase III | Cytarabine + Methotrexate + Ponatinib Dexamethasone + Ponatinib + Vincristine Sulfate Ponatinib + Prednisone + Vincristine Sulfate Dexamethasone + Imatinib + Vincristine Sulfate Cytarabine + Imatinib + Methotrexate Imatinib + Prednisone + Vincristine Sulfate | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | Active, not recruiting | USA | TUR | POL | ITA | GRC | FRA | FIN | ESP | CAN | BRA | BGR | AUT | AUS | ARG | 6 |